06/05/2024
Panakeia is pleased to announce that we are partnered with Medasense to distribute Medasense's PMD-200 device to the United States government institutions. The PMD-200 device offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication. Medasense’s flagship product, the PMD-200™ with its NOL – Nociception Level Index®, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and a proprietary non- invasive sensor platform.
Ramat Gan, Israel, May 2024 — Medasense, a pioneer in pain monitoring technology, has announced a strategic agreement with Panakeia,